Document Detail


Novel molecular targets for atrial fibrillation therapy.
MedLine Citation:
PMID:  22460122     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Atrial fibrillation is the most common type of cardiac arrhythmia, and is responsible for substantial morbidity and mortality in the general population. Current treatments have moderate efficacy and considerable risks, especially of pro-arrhythmia, highlighting the need for new therapeutic strategies. In recent years, substantial efforts have been invested in developing novel treatments that target the underlying molecular determinants of atrial fibrillation, and several new compounds are under development. This Review focuses on the mechanistic rationale for the development of new anti-atrial fibrillation drugs, on the molecular and structural motifs that they target and on the results obtained so far in experimental and clinical studies.
Authors:
Dobromir Dobrev; Leif Carlsson; Stanley Nattel
Publication Detail:
Type:  Journal Article     Date:  2012-03-30
Journal Detail:
Title:  Nature reviews. Drug discovery     Volume:  11     ISSN:  1474-1784     ISO Abbreviation:  Nat Rev Drug Discov     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-03-30     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101124171     Medline TA:  Nat Rev Drug Discov     Country:  England    
Other Details:
Languages:  eng     Pagination:  275-91     Citation Subset:  IM    
Affiliation:
Division of Experimental Cardiology, Medical Faculty Mannheim, University of Heidelberg, 68167 Mannheim, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Aflibercept.
Next Document:  Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain.